DNMT1 and breast carcinoma: SGI-021 is a non-nucleoside DNMT inhibitor that exerts a potent anti-proliferative effect against cancer cell lines derived from breast cancer, histiocytic lymphoma, Burkitt’s lymphoma and prostate cancer (Datta et al., 2009).